The preliminary findings on clinical trials into the cognitive benefit of nootropic beverages made by Koios Beverage Corp. (OTC: KBEVF) (CSE: KBEV) (the “Company” or “Koios”), indicate positive brain results, the Company reported today.
So far, full clinical brain scans on Koios users show changes in brain activity in three main areas, all of which indicate improved cognitive function.
“The findings, although preliminary, are better than we could have expected,” said Chris Miller, CEO of the Company. “Changes in the type of brain activity that we are seeing between the baseline that was mapped at the start of the study, and the effect on participants after several months of consuming our beverages, could have many positive implications.”
The study is being conducted by NeuraPerformance/Neuroptimize Brain Center, the go-to brain lab and physiotherapy clinic for Colorado’s elite athletes, including the Denver Broncos football team. The lab’s brain mapping technique involves using sensors to measure the electrical activity within the client’s brain.
The lab reported three initial findings of significance: a decrease in slow brain-wave activity, (delta and theta) which for many people “can lead to quicker thought processes, better energy, sharper focus and an overall sense of mind clarity,” says Rachel Ragsdale, founder and CEO of Neuroptimize.
The second key finding was an increase in alpha activity, linked with overall intelligence. The third finding was an increase in fast activity (beta and high beta). “This brain wave is needed to feel alert, focused, and motivated,” said Ragsdale, an accredited Board Certified Neurofeedback Therapist. “Seeing an increase in this brain wave could have many implications relating to the overall drive and energy of a person that might lack beta and is a very positive finding.”
NeuraPerformance/Neuroptimize is expected to release a full report within the next month, after which it will begin further testing the Company’s proprietary nootropic formula with CBDs. This will make Koios one of the first, if not the first, beverage company to run tests on its cannabis-infused nootropic beverages, which it is developing under its Cannavated subsidiary for the legal medical and recreational marijuana market.
Koios is a leading innovator in the nootropic beverage industry, making functional beverages that are augmented with nutrients and/or supplements to convey a health benefit to the consumer.